Wedbush Securities’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $64K | Hold |
40,850
| – | – | ﹤0.01% | 1214 |
|
|
2025
Q4 | $47K | Hold |
40,850
| – | – | ﹤0.01% | 1195 |
|
|
2025
Q3 | $55K | Hold |
40,850
| – | – | ﹤0.01% | 1151 |
|
|
2025
Q2 | $39K | Hold |
40,850
| – | – | ﹤0.01% | 1144 |
|
|
2025
Q1 | $19K | Hold |
40,850
| – | – | ﹤0.01% | 1105 |
|
|
2024
Q4 | $30K | Hold |
40,850
| – | – | ﹤0.01% | 1125 |
|
|
2024
Q3 | $64K | Hold |
40,850
| – | – | ﹤0.01% | 1072 |
|
|
2024
Q2 | $69K | Sell |
40,850
-800
| -2% | -$1.44K | ﹤0.01% | 1162 |
|
|
2024
Q1 | $100K | Buy |
+41,650
| New | +$89.5K | ﹤0.01% | 1180 |
|
|
2020
Q4 | – | Sell |
-320,509
| Closed | -$462K | – | 931 |
|
|
2020
Q3 | $462K | Sell |
320,509
-66,526
| -17% | -$118K | 0.04% | 450 |
|
|
2020
Q2 | $772K | Buy |
387,035
+32,750
| +9% | +$64.2K | 0.07% | 280 |
|
|
2020
Q1 | $691K | Sell |
354,285
-13,377
| -4% | -$39.8K | 0.08% | 273 |
|
|
2019
Q4 | $1.53M | Sell |
367,662
-31,022
| -8% | -$119K | 0.14% | 171 |
|
|
2019
Q3 | $1.2M | Buy |
398,684
+204,345
| +105% | +$633K | 0.12% | 202 |
|
|
2019
Q2 | $1.22M | Buy |
194,339
+48,182
| +33% | +$288K | 0.12% | 192 |
|
|
2019
Q1 | $813K | Sell |
146,157
-28,285
| -16% | -$172K | 0.09% | 263 |
|
|
2018
Q4 | $1.16M | Buy |
174,442
+49,312
| +39% | +$399K | 0.15% | 167 |
|
|
2018
Q3 | $1.33M | Sell |
125,130
-26,220
| -17% | -$300K | 0.15% | 148 |
|
|
2018
Q2 | $1.82M | Sell |
151,350
-4,046
| -3% | -$41.4K | 0.23% | 93 |
|
|
2018
Q1 | $1.33M | Buy |
155,396
+16,290
| +12% | +$151K | 0.17% | 132 |
|
|
2017
Q4 | $1.37M | Buy |
139,106
+26,873
| +24% | +$279K | 0.17% | 135 |
|
|
2017
Q3 | $1.38M | Buy |
112,233
+24,593
| +28% | +$363K | 0.18% | 120 |
|
|
2017
Q2 | $1.44M | Buy |
87,640
+34,586
| +65% | +$536K | 0.19% | 113 |
|
|
2017
Q1 | $761K | Buy |
53,054
+33,140
| +166% | +$492K | 0.1% | 239 |
|
|
2016
Q4 | $275K | Buy |
+19,914
| New | +$320K | 0.04% | 538 |
|
|
2015
Q2 | – | Sell |
-5,457
| Closed | -$36K | – | 751 |
|
|
2015
Q1 | $36K | Buy |
+5,457
| New | +$37.3K | 0.01% | 707 |
|
|
2014
Q4 | – | Sell |
-1,429
| Closed | -$14K | – | 738 |
|
|
2014
Q3 | $14K | Hold |
1,429
| – | – | ﹤0.01% | 683 |
|
|
2014
Q2 | $16K | Hold |
1,429
| – | – | ﹤0.01% | 654 |
|
|
2014
Q1 | $17K | Hold |
1,429
| – | – | ﹤0.01% | 619 |
|
|
2013
Q4 | $18K | Hold |
1,429
| – | – | ﹤0.01% | 580 |
|
|
2013
Q3 | $24K | Hold |
1,429
| – | – | 0.01% | 570 |
|
|
2013
Q2 | $22K | Buy |
+1,429
| New | +$21.7K | 0.01% | 546 |
|
Other funds holding LXRX
AG
SL
SC
VCM
Wedbush Securities's LXRX Position: Q1 2026 in Review
Wedbush Securities held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2026 at 40,850 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #1214.
Wedbush Securities first reported a position in LXRX in Q2 2013 and has held it in 32 quarters since. The position peaked at $1.82M in Q2 2018. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.
- Wedbush Securities held 40,850 shares of Lexicon Pharmaceuticals worth $64K as of Q1 2026.
- Wedbush Securities left its Lexicon Pharmaceuticals share count unchanged in Q1 2026.
- Lexicon Pharmaceuticals made up ﹤0.01% of Wedbush Securities's portfolio in Q1 2026, its #1214 holding.
- Wedbush Securities first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
- Wedbush Securities's Lexicon Pharmaceuticals position peaked at $1.82M in Q2 2018.
- 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.
Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.